Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The effect of chronic lorazepam administration in aging mice.

Fahey JM, Pritchard GA, Reddi JM, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ.

Brain Res. 2006 Nov 6;1118(1):13-24. Epub 2006 Sep 20.

PMID:
16989785
2.

Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses.

Fahey JM, Grassi JM, Reddi JM, Greenblatt DJ.

Pharmacol Biochem Behav. 2006 Jan;83(1):21-7. Epub 2006 Jan 24.

PMID:
16439007
3.

Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice.

von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ.

Drug Metab Dispos. 2004 Aug;32(8):800-4.

PMID:
15258104
4.

Pharmacodynamic and receptor binding changes during chronic lorazepam administration.

Fahey JM, Pritchard GA, Grassi JM, Pratt JS, Shader RI, Greenblatt DJ.

Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):1-8.

PMID:
11420062
5.

In situ hybridization histochemistry as a method to assess GABA(A) receptor subunit mRNA expression following chronic alprazolam administration.

Fahey JM, Pritchard GA, Grassi JM, Pratt JS, Shader RI, Greenblatt DJ.

J Psychopharmacol. 1999;13(3):211-8.

PMID:
10512074
6.

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI.

Biol Psychiatry. 1999 Sep 15;46(6):839-49.

PMID:
10494454
7.

Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.

von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI.

Psychopharmacology (Berl). 1999 Jul;145(1):113-22.

PMID:
10445380
8.

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.

Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI.

Br J Clin Pharmacol. 1999 Jul;48(1):89-97.

9.

Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, Shader RI.

Psychopharmacology (Berl). 1998 Dec;140(3):293-9.

PMID:
9877009
10.

Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI.

J Pharm Pharmacol. 1998 Sep;50(9):997-1004.

PMID:
9811160
11.

Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine.

von Moltke LL, Greenblatt DJ, Ciraulo DA, Grassi JM, Granda BW, Duan SX, Harmatz JS, Shader RI.

J Clin Psychopharmacol. 1998 Aug;18(4):338-41.

PMID:
9690701
12.

Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.

Fahey JM, Pritchard GA, Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ.

J Pharmacol Exp Ther. 1998 Apr;285(1):271-6.

PMID:
9536021
13.

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI.

J Clin Pharmacol. 1998 Feb;38(2):106-11.

PMID:
9549640

Supplemental Content

Loading ...
Support Center